公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)! YZ剂描述: 产品名称:GDC-0077 产品别名:见爱必信官网 英文别名:GDC-0077 靶点:PI3K;Apoptosis CAS:2060571-02-8 纯度:98% 外观:见爱必信官网 保存方法:store at -20℃ for one year(Powder) 描述:GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I. 溶解性: In Vitro: DMSO : ≥ 180 mg/mL (441.86 mM) * "≥" means soluble, but saturation unknown. Preparing Stock Solutions ConcentrationSolventMass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.4548 mL | 12.2739 mL | 24.5477 mL | 5 mM | 0.4910 mL | 2.4548 mL | 4.9095 mL | 10 mM | 0.2455 mL | 1.2274 mL | 2.4548 mL |
*请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存方式和期限。 体外研究: GDC-0077 (RG6114) is >300-fold more selective for PI3Kα over the other class I PI3K isoforms (β, δ, and γ) and >2000-fold more selective over PIK family members. GDC-0077 selectively degrades mutant PI3Kα in a proteasome-dependent fashion resulting in reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation, and increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent when compared to PIK3CA wild-type cells. 体内研究: GDC-0077 (p.o.) results in tumor regressions, induction of apoptosis, and a reduction of pAKT, pPRAS40, and pS6RP in a dose-dependent fashion in patient-derived PIK3CA-mutant breast cancer xenograft models. 产品信息订购: 产品货号 | 产品名称 | 规格 | 价格 | 大包装及货期 | abs821492 | GDC-0077 | 1mg | 1800 | 立即咨询 | 产品更多信息请进入爱必信网站咨询 |